CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Capex Y/Y Annual
Syros Pharmaceuticals Inc   (NASDAQ: SYRS)
Other Ticker:  
 
 

SYRS's Capital Expenditures Growth by Quarter and Year

Syros Pharmaceuticals Inc 's Capital Expenditures results by quarter and year

 



SYRS Capital Expenditures (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December - 0.04 0.67 0.25
3rd Quarter September 0.00 0.00 0.33 0.31
2nd Quarter June 0.00 0.00 0.11 0.43
1st Quarter March 0.00 0.24 0.13 0.26
FY   0.00 0.28 1.24 1.25

SYRSs Annual Capital Expenditures
Syros Pharmaceuticals Inc 's Capital Expenditures in the fiscal year 2023 $ 0.27 millions
Syros Pharmaceuticals Inc 's Capital Expenditures in the fiscal year 2022 $ 1.24 millions
Syros Pharmaceuticals Inc 's Capital Expenditures in the fiscal year 2021 $ 1.25 millions
Syros Pharmaceuticals Inc 's Capital Expenditures in the fiscal year 2020 $ 3.34 millions
Syros Pharmaceuticals Inc 's Capital Expenditures in the fiscal year 2019 $ 12.64 millions




SYRS Capital Expenditures third quarter 2024 Y/Y Growth Comment
Syros Pharmaceuticals Inc in the third quarter 2024 recorded Capital Expenditures of $ 0.00 millions.

According to the results reported in the third quarter 2024, Syros Pharmaceuticals Inc achieved the best Capital Expenditures growth in Major Pharmaceutical Preparations industry. While Syros Pharmaceuticals Inc ' s Capital Expenditures no change of 0% ranks overall at the positon no. in the third quarter 2024.


SYRS Capital Expenditures ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - -94.03 % 168 % 733.33 %
3rd Quarter September - - 6.45 % -40.38 %
2nd Quarter June - - -74.42 % -56.57 %
1st Quarter March - 84.62 % -50 % -85.56 %
FY   - -77.42 % -0.8 % -62.57 %

Financial Statements
Syros Pharmaceuticals Inc 's third quarter 2024 Capital Expenditures $ 0.00 millions SYRS's Income Statement
Syros Pharmaceuticals Inc 's third quarter 2023 Capital Expenditures $ 0.00 millions Quarterly SYRS's Income Statement


SYRS Capital Expenditures (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - - 103.03 % -19.35 %
3rd Quarter September - - 200 % -27.91 %
2nd Quarter June - - -15.38 % 65.38 %
1st Quarter March - -64.18 % -48 % 766.67 %
FY (Year on Year)   - -77.42 % -0.8 % -62.57 %


Suppliers by SYRS Divisions >> Back to SYRS Growth rate Comparisons >>


Capital Expenditures third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Capital Expenditures Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Capital Expenditures third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Capital Expenditures Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Capital Expenditures by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Syros Pharmaceuticals Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


SYRS's III. Quarter Q/Q Capital Expenditures Comment


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Capital Expenditures Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


SYRS's III. Quarter Q/Q Capital Expenditures Comment


Syros Pharmaceuticals Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)
Cumulative Capital Expenditures 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Capital Expenditures Growth (TTM) - - - - -
Year on Year Capital Expenditures Growth Overall Ranking # # # # #
Seqeuential Capital Expenditures Change (TTM) - - - - -
Seq. Capital Expenditures Growth (TTM) Overall Ranking # # # # #


Cumulative Capital Expenditures growth Comment
In the Sep 30 2024 period, Syros Pharmaceuticals Inc 's cumulative trailing twelve month Capital Expenditures remained unchanged compare to the same period a year ago.

Syros Pharmaceuticals Inc achieved highest trailing twelve month year on year Capital Expenditures growth. While overall Capital Expenditures growth ranking, remained unchanged compare to the previous quarter at no. .

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Capital Expenditures growth Comment
In the Sep 30 2024 period, Syros Pharmaceuticals Inc 's cumulative trailing twelve month Capital Expenditures remained unchanged compare to the same period a year ago.

Syros Pharmaceuticals Inc achieved highest trailing twelve month year on year Capital Expenditures growth. While overall Capital Expenditures growth ranking, remained unchanged compare to the previous quarter at no. .


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
SYRS's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for SYRS's Competitors
Capital Expenditures Growth for Syros Pharmaceuticals Inc 's Suppliers
Capital Expenditures Growth for SYRS's Customers

You may also want to know
SYRS's Annual Growth Rates SYRS's Profitability Ratios SYRS's Asset Turnover Ratio SYRS's Dividend Growth
SYRS's Roe SYRS's Valuation Ratios SYRS's Financial Strength Ratios SYRS's Dividend Payout Ratio
SYRS's Roa SYRS's Inventory Turnover Ratio SYRS's Growth Rates SYRS's Dividend Comparisons



Companies with similar Capital Expenditures no change for the quarter ending Sep 30 2024 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Sep 30 2024
Atricure Inc -0.61%$ -0.606 millions
Hims and Hers Health Inc -0.66%$ -0.659 millions
Abbott Laboratories-0.71%$ -0.714 millions
U S Physical Therapy Inc-1.10%$ -1.098 millions
Azitra Inc -2.07%$ -2.069 millions
23andme Holding Co -2.24%$ -2.236 millions
Irhythm Technologies Inc -2.78%$ -2.784 millions
Intuitive Surgical Inc -3.28%$ -3.277 millions
Tscan Therapeutics Inc -3.45%$ -3.453 millions
Urogen Pharma Ltd -4.00%$ -4.000 millions
Cormedix Inc-4.68%$ -4.675 millions
Cvrx inc -5.13%$ -5.128 millions
Bristol myers Squibb Company-5.26%$ -5.263 millions
Boston Scientific Corporation-5.79%$ -5.789 millions
Athira Pharma Inc -6.67%$ -6.667 millions
Icu Medical Inc-6.90%$ -6.902 millions
Alphatec Holdings Inc -7.04%$ -7.038 millions
Warby Parker Inc -8.17%$ -8.168 millions
Eyepoint Pharmaceuticals Inc -8.49%$ -8.488 millions
Bio rad Laboratories Inc -8.72%$ -8.718 millions
Sarepta Therapeutics Inc -8.92%$ -8.919 millions
Tela Bio Inc -8.96%$ -8.955 millions
Biomarin Pharmaceutical Inc-9.58%$ -9.578 millions
Lexeo Therapeutics Inc -9.78%$ -9.783 millions
Diamedica Therapeutics Inc-10.00%$ -10.000 millions
Abcellera Biologics Inc -11.37%$ -11.369 millions
Zymeworks Inc -11.72%$ -11.718 millions
Verve Therapeutics Inc -11.78%$ -11.781 millions
Apyx Medical Corp-12.07%$ -12.069 millions
Fate Therapeutics Inc -12.39%$ -12.389 millions


Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com